![NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)](https://jnccn.org/cover/journals/jnccn/17/6/cover.jpg)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 6 (2019)
![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/3cc43973-9161-436d-bf55-be5a18c2f548/gr1.gif)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet
![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/f8ef32d8-e2f9-4baf-b793-4a1ee10fea30/gr2_lrg.jpg)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet
![Current Oncology | Free Full-Text | Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma Current Oncology | Free Full-Text | Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma](https://pub.mdpi-res.com/curroncol/curroncol-28-00407/article_deploy/html/images/curroncol-28-00407-g001a.png?1637282444)
Current Oncology | Free Full-Text | Low-Grade Primary Splenic CD10-Positive Small B-Cell Lymphoma/Follicular Lymphoma
![Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group - Alonso‐Álvarez - 2017 - British Journal of Haematology - Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group - Alonso‐Álvarez - 2017 - British Journal of Haematology -](https://onlinelibrary.wiley.com/cms/asset/ae722ee4-543d-4fb2-a7bc-94d3ca31eee7/bjh.2017.178.issue-5.cover.jpg?trick=1670505376531)